ara c Search Results


cytosine arabinoside  (MedChemExpress)
97
MedChemExpress cytosine arabinoside
Cytosine Arabinoside, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cytosine arabinoside/product/MedChemExpress
Average 97 stars, based on 1 article reviews
cytosine arabinoside - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier
pure r car  (Chem Impex International)
95
Chem Impex International pure r car
Pure R Car, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pure r car/product/Chem Impex International
Average 95 stars, based on 1 article reviews
pure r car - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
pbest or2 or1 pr arac  (Addgene inc)
92
Addgene inc pbest or2 or1 pr arac
Pbest Or2 Or1 Pr Arac, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pbest or2 or1 pr arac/product/Addgene inc
Average 92 stars, based on 1 article reviews
pbest or2 or1 pr arac - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier
ara c  (TargetMol)
94
TargetMol ara c
Ara C, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ara c/product/TargetMol
Average 94 stars, based on 1 article reviews
ara c - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
psam arac  (Addgene inc)
93
Addgene inc psam arac
Psam Arac, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/psam arac/product/Addgene inc
Average 93 stars, based on 1 article reviews
psam arac - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
cytarabine hcl  (MedChemExpress)
93
MedChemExpress cytarabine hcl
a Principal component analysis (PCA) of the initial drug screen with circles colored based on categorization using metric quartiles into enhancers, inhibitors, and neutral compounds for outcomes attributed to MMEJ, HDR, and NHEJ. PC1 and PC2 separate MMEJ, whereas. PC3 and PC4 separate HDR and NHEJ. The right panel shows the direction of the PCA vectors per metric and percentage of data variation explained by PC3 and PC4. For categorization filters, see Supplementary Fig. . b Numbers of categorized enhancers and inhibitors from the initial screen, as well as those of the subset screen. Enhancers shown in orange, inhibitors in purple. c Heatmap of relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit FRMD7 using different drugs and their respective effective concentration. Asterisks indicate normalized MMEJ changes based on the method’s detection limit for MMEJ reduction (full inhibition = 0.74 for POLQ knock-out ). d Heatmap of selected drugs at effective concentration with relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit NOVA1 . e Effects of combinations of tolterodine (10 µM), orphenadrine (10 µM), and M3814 (2 µM) on genome editing efficiencies of FRMD7 , NOVA1 , and VCAN in iCas9 409B2 hiPSCs and of SV2C with Cas9-HiFi RNP in HEK293. For precise edits, replicates are depicted by dots. Independent biological replicates were performed ( n = 2 for b , c ; n = 6 for d ouabain, duloxetine, cyproterone, n = 3 for d artemether, <t>cytarabine,</t> myristic acid; n = 3 for e ). Error bars indicate the s.e.m. Source data are provided as a Source Data file.
Cytarabine Hcl, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cytarabine hcl/product/MedChemExpress
Average 93 stars, based on 1 article reviews
cytarabine hcl - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
cytosine β darabinofuranoside  (Valiant Co Ltd)
94
Valiant Co Ltd cytosine β darabinofuranoside
a Principal component analysis (PCA) of the initial drug screen with circles colored based on categorization using metric quartiles into enhancers, inhibitors, and neutral compounds for outcomes attributed to MMEJ, HDR, and NHEJ. PC1 and PC2 separate MMEJ, whereas. PC3 and PC4 separate HDR and NHEJ. The right panel shows the direction of the PCA vectors per metric and percentage of data variation explained by PC3 and PC4. For categorization filters, see Supplementary Fig. . b Numbers of categorized enhancers and inhibitors from the initial screen, as well as those of the subset screen. Enhancers shown in orange, inhibitors in purple. c Heatmap of relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit FRMD7 using different drugs and their respective effective concentration. Asterisks indicate normalized MMEJ changes based on the method’s detection limit for MMEJ reduction (full inhibition = 0.74 for POLQ knock-out ). d Heatmap of selected drugs at effective concentration with relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit NOVA1 . e Effects of combinations of tolterodine (10 µM), orphenadrine (10 µM), and M3814 (2 µM) on genome editing efficiencies of FRMD7 , NOVA1 , and VCAN in iCas9 409B2 hiPSCs and of SV2C with Cas9-HiFi RNP in HEK293. For precise edits, replicates are depicted by dots. Independent biological replicates were performed ( n = 2 for b , c ; n = 6 for d ouabain, duloxetine, cyproterone, n = 3 for d artemether, <t>cytarabine,</t> myristic acid; n = 3 for e ). Error bars indicate the s.e.m. Source data are provided as a Source Data file.
Cytosine β Darabinofuranoside, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cytosine β darabinofuranoside/product/Valiant Co Ltd
Average 94 stars, based on 1 article reviews
cytosine β darabinofuranoside - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
pjkr h arac  (Addgene inc)
93
Addgene inc pjkr h arac
a Principal component analysis (PCA) of the initial drug screen with circles colored based on categorization using metric quartiles into enhancers, inhibitors, and neutral compounds for outcomes attributed to MMEJ, HDR, and NHEJ. PC1 and PC2 separate MMEJ, whereas. PC3 and PC4 separate HDR and NHEJ. The right panel shows the direction of the PCA vectors per metric and percentage of data variation explained by PC3 and PC4. For categorization filters, see Supplementary Fig. . b Numbers of categorized enhancers and inhibitors from the initial screen, as well as those of the subset screen. Enhancers shown in orange, inhibitors in purple. c Heatmap of relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit FRMD7 using different drugs and their respective effective concentration. Asterisks indicate normalized MMEJ changes based on the method’s detection limit for MMEJ reduction (full inhibition = 0.74 for POLQ knock-out ). d Heatmap of selected drugs at effective concentration with relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit NOVA1 . e Effects of combinations of tolterodine (10 µM), orphenadrine (10 µM), and M3814 (2 µM) on genome editing efficiencies of FRMD7 , NOVA1 , and VCAN in iCas9 409B2 hiPSCs and of SV2C with Cas9-HiFi RNP in HEK293. For precise edits, replicates are depicted by dots. Independent biological replicates were performed ( n = 2 for b , c ; n = 6 for d ouabain, duloxetine, cyproterone, n = 3 for d artemether, <t>cytarabine,</t> myristic acid; n = 3 for e ). Error bars indicate the s.e.m. Source data are provided as a Source Data file.
Pjkr H Arac, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pjkr h arac/product/Addgene inc
Average 93 stars, based on 1 article reviews
pjkr h arac - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
aplasia inducing chemotherapy consisting of fludarabine, ara-c and amsacrine (flamsa)  (Schmid GmbH)
90
Schmid GmbH aplasia inducing chemotherapy consisting of fludarabine, ara-c and amsacrine (flamsa)
a Principal component analysis (PCA) of the initial drug screen with circles colored based on categorization using metric quartiles into enhancers, inhibitors, and neutral compounds for outcomes attributed to MMEJ, HDR, and NHEJ. PC1 and PC2 separate MMEJ, whereas. PC3 and PC4 separate HDR and NHEJ. The right panel shows the direction of the PCA vectors per metric and percentage of data variation explained by PC3 and PC4. For categorization filters, see Supplementary Fig. . b Numbers of categorized enhancers and inhibitors from the initial screen, as well as those of the subset screen. Enhancers shown in orange, inhibitors in purple. c Heatmap of relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit FRMD7 using different drugs and their respective effective concentration. Asterisks indicate normalized MMEJ changes based on the method’s detection limit for MMEJ reduction (full inhibition = 0.74 for POLQ knock-out ). d Heatmap of selected drugs at effective concentration with relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit NOVA1 . e Effects of combinations of tolterodine (10 µM), orphenadrine (10 µM), and M3814 (2 µM) on genome editing efficiencies of FRMD7 , NOVA1 , and VCAN in iCas9 409B2 hiPSCs and of SV2C with Cas9-HiFi RNP in HEK293. For precise edits, replicates are depicted by dots. Independent biological replicates were performed ( n = 2 for b , c ; n = 6 for d ouabain, duloxetine, cyproterone, n = 3 for d artemether, <t>cytarabine,</t> myristic acid; n = 3 for e ). Error bars indicate the s.e.m. Source data are provided as a Source Data file.
Aplasia Inducing Chemotherapy Consisting Of Fludarabine, Ara C And Amsacrine (Flamsa), supplied by Schmid GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aplasia inducing chemotherapy consisting of fludarabine, ara-c and amsacrine (flamsa)/product/Schmid GmbH
Average 90 stars, based on 1 article reviews
aplasia inducing chemotherapy consisting of fludarabine, ara-c and amsacrine (flamsa) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
5-3h]arac  (Amersham Life Sciences Inc)
90
Amersham Life Sciences Inc 5-3h]arac
a Principal component analysis (PCA) of the initial drug screen with circles colored based on categorization using metric quartiles into enhancers, inhibitors, and neutral compounds for outcomes attributed to MMEJ, HDR, and NHEJ. PC1 and PC2 separate MMEJ, whereas. PC3 and PC4 separate HDR and NHEJ. The right panel shows the direction of the PCA vectors per metric and percentage of data variation explained by PC3 and PC4. For categorization filters, see Supplementary Fig. . b Numbers of categorized enhancers and inhibitors from the initial screen, as well as those of the subset screen. Enhancers shown in orange, inhibitors in purple. c Heatmap of relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit FRMD7 using different drugs and their respective effective concentration. Asterisks indicate normalized MMEJ changes based on the method’s detection limit for MMEJ reduction (full inhibition = 0.74 for POLQ knock-out ). d Heatmap of selected drugs at effective concentration with relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit NOVA1 . e Effects of combinations of tolterodine (10 µM), orphenadrine (10 µM), and M3814 (2 µM) on genome editing efficiencies of FRMD7 , NOVA1 , and VCAN in iCas9 409B2 hiPSCs and of SV2C with Cas9-HiFi RNP in HEK293. For precise edits, replicates are depicted by dots. Independent biological replicates were performed ( n = 2 for b , c ; n = 6 for d ouabain, duloxetine, cyproterone, n = 3 for d artemether, <t>cytarabine,</t> myristic acid; n = 3 for e ). Error bars indicate the s.e.m. Source data are provided as a Source Data file.
5 3h]Arac, supplied by Amersham Life Sciences Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/5-3h]arac/product/Amersham Life Sciences Inc
Average 90 stars, based on 1 article reviews
5-3h]arac - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
l-[1-3h]ara  (Moravek Biochemicals)
90
Moravek Biochemicals l-[1-3h]ara
a Principal component analysis (PCA) of the initial drug screen with circles colored based on categorization using metric quartiles into enhancers, inhibitors, and neutral compounds for outcomes attributed to MMEJ, HDR, and NHEJ. PC1 and PC2 separate MMEJ, whereas. PC3 and PC4 separate HDR and NHEJ. The right panel shows the direction of the PCA vectors per metric and percentage of data variation explained by PC3 and PC4. For categorization filters, see Supplementary Fig. . b Numbers of categorized enhancers and inhibitors from the initial screen, as well as those of the subset screen. Enhancers shown in orange, inhibitors in purple. c Heatmap of relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit FRMD7 using different drugs and their respective effective concentration. Asterisks indicate normalized MMEJ changes based on the method’s detection limit for MMEJ reduction (full inhibition = 0.74 for POLQ knock-out ). d Heatmap of selected drugs at effective concentration with relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit NOVA1 . e Effects of combinations of tolterodine (10 µM), orphenadrine (10 µM), and M3814 (2 µM) on genome editing efficiencies of FRMD7 , NOVA1 , and VCAN in iCas9 409B2 hiPSCs and of SV2C with Cas9-HiFi RNP in HEK293. For precise edits, replicates are depicted by dots. Independent biological replicates were performed ( n = 2 for b , c ; n = 6 for d ouabain, duloxetine, cyproterone, n = 3 for d artemether, <t>cytarabine,</t> myristic acid; n = 3 for e ). Error bars indicate the s.e.m. Source data are provided as a Source Data file.
L [1 3h]Ara, supplied by Moravek Biochemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/l-[1-3h]ara/product/Moravek Biochemicals
Average 90 stars, based on 1 article reviews
l-[1-3h]ara - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
ara-c  (Astellas)
90
Astellas ara-c
a Principal component analysis (PCA) of the initial drug screen with circles colored based on categorization using metric quartiles into enhancers, inhibitors, and neutral compounds for outcomes attributed to MMEJ, HDR, and NHEJ. PC1 and PC2 separate MMEJ, whereas. PC3 and PC4 separate HDR and NHEJ. The right panel shows the direction of the PCA vectors per metric and percentage of data variation explained by PC3 and PC4. For categorization filters, see Supplementary Fig. . b Numbers of categorized enhancers and inhibitors from the initial screen, as well as those of the subset screen. Enhancers shown in orange, inhibitors in purple. c Heatmap of relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit FRMD7 using different drugs and their respective effective concentration. Asterisks indicate normalized MMEJ changes based on the method’s detection limit for MMEJ reduction (full inhibition = 0.74 for POLQ knock-out ). d Heatmap of selected drugs at effective concentration with relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit NOVA1 . e Effects of combinations of tolterodine (10 µM), orphenadrine (10 µM), and M3814 (2 µM) on genome editing efficiencies of FRMD7 , NOVA1 , and VCAN in iCas9 409B2 hiPSCs and of SV2C with Cas9-HiFi RNP in HEK293. For precise edits, replicates are depicted by dots. Independent biological replicates were performed ( n = 2 for b , c ; n = 6 for d ouabain, duloxetine, cyproterone, n = 3 for d artemether, <t>cytarabine,</t> myristic acid; n = 3 for e ). Error bars indicate the s.e.m. Source data are provided as a Source Data file.
Ara C, supplied by Astellas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ara-c/product/Astellas
Average 90 stars, based on 1 article reviews
ara-c - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


a Principal component analysis (PCA) of the initial drug screen with circles colored based on categorization using metric quartiles into enhancers, inhibitors, and neutral compounds for outcomes attributed to MMEJ, HDR, and NHEJ. PC1 and PC2 separate MMEJ, whereas. PC3 and PC4 separate HDR and NHEJ. The right panel shows the direction of the PCA vectors per metric and percentage of data variation explained by PC3 and PC4. For categorization filters, see Supplementary Fig. . b Numbers of categorized enhancers and inhibitors from the initial screen, as well as those of the subset screen. Enhancers shown in orange, inhibitors in purple. c Heatmap of relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit FRMD7 using different drugs and their respective effective concentration. Asterisks indicate normalized MMEJ changes based on the method’s detection limit for MMEJ reduction (full inhibition = 0.74 for POLQ knock-out ). d Heatmap of selected drugs at effective concentration with relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit NOVA1 . e Effects of combinations of tolterodine (10 µM), orphenadrine (10 µM), and M3814 (2 µM) on genome editing efficiencies of FRMD7 , NOVA1 , and VCAN in iCas9 409B2 hiPSCs and of SV2C with Cas9-HiFi RNP in HEK293. For precise edits, replicates are depicted by dots. Independent biological replicates were performed ( n = 2 for b , c ; n = 6 for d ouabain, duloxetine, cyproterone, n = 3 for d artemether, cytarabine, myristic acid; n = 3 for e ). Error bars indicate the s.e.m. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Repurposing clinically safe drugs for DNA repair pathway choice in CRISPR genome editing and synthetic lethality

doi: 10.1038/s41467-025-67243-0

Figure Lengend Snippet: a Principal component analysis (PCA) of the initial drug screen with circles colored based on categorization using metric quartiles into enhancers, inhibitors, and neutral compounds for outcomes attributed to MMEJ, HDR, and NHEJ. PC1 and PC2 separate MMEJ, whereas. PC3 and PC4 separate HDR and NHEJ. The right panel shows the direction of the PCA vectors per metric and percentage of data variation explained by PC3 and PC4. For categorization filters, see Supplementary Fig. . b Numbers of categorized enhancers and inhibitors from the initial screen, as well as those of the subset screen. Enhancers shown in orange, inhibitors in purple. c Heatmap of relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit FRMD7 using different drugs and their respective effective concentration. Asterisks indicate normalized MMEJ changes based on the method’s detection limit for MMEJ reduction (full inhibition = 0.74 for POLQ knock-out ). d Heatmap of selected drugs at effective concentration with relative fold-changes of HDR, MMEJ, NHEJ, and survival using an inducible Cas9 in 409B2 hiPSCs to edit NOVA1 . e Effects of combinations of tolterodine (10 µM), orphenadrine (10 µM), and M3814 (2 µM) on genome editing efficiencies of FRMD7 , NOVA1 , and VCAN in iCas9 409B2 hiPSCs and of SV2C with Cas9-HiFi RNP in HEK293. For precise edits, replicates are depicted by dots. Independent biological replicates were performed ( n = 2 for b , c ; n = 6 for d ouabain, duloxetine, cyproterone, n = 3 for d artemether, cytarabine, myristic acid; n = 3 for e ). Error bars indicate the s.e.m. Source data are provided as a Source Data file.

Article Snippet: For further drug testing, ART558 (MedChemExpress, catalog no. HY-141520), artemether (MedChemExpress, catalog no. HY-N0402), B02 (Sigma, catalog no. HY-101462), bromfenac sodium (MedChemExpress, catalog no. HY-B1888A), cisplatin (MedChemExpress, catalog no. HY-17394), doxorubicin (MedChemExpress, catalog no. HY-15142A), cyproterone acetate (MedChemExpress, catalog no. HY-13604), cytarabine HCl (MedChemExpress, catalog no. HY-13605A), dantrolene sodium salt (ApexBio, catalog no. B6329), dronedarone HCl (MedChemExpress, catalog no. HY-75839), duloxetine HCl (MedChemExpress, catalog no. HY-B0161A), erlotinib HCl (Sigma-Aldrich, catalog no. SML2156), gefitinib (Sigma-Aldrich, catalog no. SML1657), hodostin (neostigmine methyl sulfate; MedChemExpress, catalog no. HY-B1206), isosorbide 5-mononitrate (MedChemExpress, catalog no. HY-B0642), loperamide HCl (MedChemExpress, catalog no. HY-B0418A), M3814 (MedChemExpress, catalog no. HY-101570), myristic acid (MedChemExpress, catalog no. HY-N2041), olaparib (MedChemExpress, catalog no. HY-10162), ouabain octahydrate (MedChemExpress, catalog no. HY-B0542), raloxifene HCl (Sigma-Aldrich, catalog no. 1598201), rucaparib (MedChemExpress, catalog no. HY-10617A), were used.

Techniques: Concentration Assay, Inhibition, Knock-Out